Adjuvant Development

decorative image
Credit: NIAID

The Adjuvant Development program supports the preclinical development of novel adjuvants for use in vaccines targeting infectious diseases or of tolerogenic / immune deviating adjuvants for treatment of immune-mediating diseases.

Data generated from supported studies are made publicly available through the Vaccine Adjuvant Compendium (VAC), enabling the rational selection of adjuvants and the future development of more effective vaccines against infectious diseases, and/or new vaccines to treat allergic or autoimmune diseases.

Main Areas of Focus

  • Preclinical development of novel adjuvants coupled with antigens, including mechanistic analyses of the novel adjuvant/antigen combinations
  • Formulation and stability studies
  • Optimization of immunization regimens and delivery routes
  • Toxicology testing
  • Pharmacokinetics/absorption, distribution, metabolism, and excretion studies
  • Clinical good manufacturing processes (cGMP) production

Featured Research

Carbohydrate Fatty Acid Monosulphate: Oil-in-water Adjuvant Enhances SARS-CoV-2 RBD Nanoparticle-induced Immunogenicity and Protection in Mice

Shaping Neonatal Immunization by Tuning the Delivery of Synergistic Adjuvants via Nanocarriers

Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine

Evaluating the Efficacy and Safety of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 Spike Protein Vaccine: A Phase 3 Randomized Placebo-Controlled Trial

A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens

Funding

Small Business Innovative Research (SBIR) Program solicitation PHS-2024-1

September 2022 DMID Council-Approved Concepts

Notice of Special Interest

Previous Funding

NIAID Vaccine Adjuvant Development Program in Infectious and Immune-Mediated Diseases

Contact Information

Content last reviewed on